Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer

International Journal of Nanomedicine

Volumn 9, Issue , 2014, Pages 5001-5011

  Axiak Bechtel, Sandra M ^a   Upendran, Anandhi ^b,c   Lattimer, Jimmy C ^a   Kelsey, James ^b,c   Cutler, Cathy S ^b   Selting, Kim A ^a   Bryan, Jeffrey N ^a   Henry, Carolyn J ^a,d   Boote, Evan ^e   Tate, Deborah J ^a   Bryan, Margaret E ^a   Katti, Kattesh V ^c,d   Kannan, Raghuraman ^c,d  

^a Department of Veterinary Medicine and Surgery ^*  (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Shasun NBI LLC   (United States)

^d University of Missouri   (United States)

^e SPECTRUM HEALTH   (United States)

Author keywords

Brachytherapy; Prostatic cancer; Safety trial

Indexed keywords

GOLD NANOPARTICLE; GOLD NANOPARTICLE AU 198; GUM ARABIC; UNCLASSIFIED DRUG; GOLD; METAL NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BRACHYTHERAPY; CONTROLLED STUDY; DOG; DOSIMETRY; DRUG COATING; MALE; NONHUMAN; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RISK ASSESSMENT; URETHRA OBSTRUCTION; URINALYSIS; ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; PATHOLOGY; PROSTATIC NEOPLASMS; RADIOGRAPHY; VETERINARY;

ANIMALS; BRACHYTHERAPY; DOGS; GOLD; GUM ARABIC; MALE; METAL NANOPARTICLES; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84927923776     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S67333     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1): 10-29.
2. Crook J. The role of brachytherapy in the definitive management of prostate cancer. Cancer Radiother. 2011; 15(3): 230-237.
3. Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2005; 17(4): 219-227.
4. Dauffy LS, Braby LA, Berner BM. Dosimetry of the 198Au source used in interstitial brachytherapy. Med Phys. 2005; 32(6): 1579-1588.
5. Podder TK, Dicker AP, Hutapea P, Darvish K, Yu Y. A novel curvilinear approach for prostate seed implantation. Med Phys. 2012; 39(4): 1887-1892.
6. Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol. 2011; 185(2): 495-500.
7. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol. 1999; 162(2): 421-426.
8. Butler EB, Scardino PT, Teh BS, et al. The Baylor College of Medicine experience with gold seed implantation. Semin Surg Oncol. 1997; 13(6): 406-418.
9. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004; 71(1): 29-33.
10. Kannan R, Rahing V, Cutler C, et al. Nanocompatible chemistry toward fabrication of target-specific gold nanoparticles. J Am Chem Soc. 2006; 128(35): 11342-11343.
11. Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012; 40(1): 21-41.
12. Papasani MR, Wang G, Hill RA. Gold nanoparticles: the importance of physiological principles to devise strategies for targeted drug delivery. Nanomedicine. 2012; 8(6): 804-814.
13. Kattumuri V, Katti K, Bhaskaran S, et al. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: in vivo pharmacokinetics and X-ray-contrast-imaging studies. Small. 2007; 3(2): 333-341.
14. Boote E, Fent G, Kattumuri V, et al. Gold nanoparticle contrast in a phantom and juvenile swine: models for molecular imaging of human organs using x-ray computed tomography. Acad Radiol. 2010; 17(4): 410-417.
15. Kannan R, Zambre A, Chanda N, et al. Functionalized radioactive gold nanoparticles in tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012; 4(1): 42-51.
16. Chanda N, Kan P, Watkinson LD, et al. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomedicine. 2010; 6(2): 201-209.
17. Li Y, Wu P, Xu H, Zhang H, Zhong X. Anti-aggregation of gold nanoparticle-based colorimetric sensor for glutathione with excellent selectivity and sensitivity. Analyst. 2011; 136(1): 196-200.
18. Whelove OE, Cozad MJ, Lee BD, et al. Development and in vitro studies of a polyethylene terephthalate-gold nanoparticle scaffold for improved biocompatibility. J Biomed Mater Res B Appl Biomater. 2011; 99(1): 142-149.
19. Lystvet SM, Volden S, Yasuda M, Halskau Ø Jr, Glomm WR. Emergent membrane-affecting properties of BSA-gold nanoparticle constructs. Nanoscale. 2011; 3(4): 1788-1797.
20. Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004; 31(3): 633-674.
21. Porter AT, Forman JD. Prostate brachytherapy. An overview. Cancer. 1993; 71(3 Suppl): 953-958.
22. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 148(6): 435-448.
23. Chowning SL, Susil RC, Krieger A, Fichtinger G, Whitcomb LL, Atalar E. A preliminary analysis and model of prostate injection distributions. Prostate. 2006; 66(4): 344-357.
24. Leroy BE, Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Vet J. 2009; 180(2): 149-162.
25. Liang CH, Wang CC, Lin YC, Chen CH, Wong CH, Wu CY. Iron oxide/gold core/shell nanoparticles for ultrasensitive detection of carbohydrate-protein interactions. Anal Chem. 2009; 81(18): 7750-7756.
26. Conversano F, Soloperto G, Greco A, et al. Echographic detectability of optoacoustic signals from low-concentration PEG-coated gold nanorods. Int J Nanomedicine. 2012; 7: 4373-4389.
27. Hainfeld JF, O'Connor MJ, Dilmanian FA, Slatkin DN, Adams DJ, Smilowitz HM. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br J Radiol. 2011; 84(1002): 526-533.
28. Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R. Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study. Int J Nanomedicine. 2011; 6: 2859-2864.
29. Grabtchak S, Tonkopi E, Whelan WM. Optical detection of gold nanoparticles in a prostate-shaped porcine phantom. J Biomed Opt. 2013; 18(7): 077005.
30. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol. 2010; 40(4): 328-346.
31. Li YF, Chen C. Fate and toxicity of metallic and metal-containing nanoparticles for biomedical applications. Small. 2011; 7(21): 2965-2980.
32. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008; 29(12): 1912-1919.
33. Fent GM, Casteel SW, Kim DY, et al. Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. Nanomedicine. 2009; 5(2): 128-135.
34. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006; 79(939): 248-253.
35. Bryan JN, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW. A population study of neutering status as a risk factor for canine prostate cancer. Prostate. 2007; 67(11): 1174-1181.
36. Cornell KK, Bostwick DG, Cooley DM, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate. 2000; 45(2): 173-183.